NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-α and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs

Pharmacological Research

Volumn 49, Issue 3, 2004, Pages 199-206

  Yin, Weidong ^a,b   Liao, Duanfang ^a,b   Wang, Zongbao ^a   Xi, Shoumin ^a   Tsutsumi, Kazuhiko ^c   Koike, Tomonari ^d   Fan, Jianglin ^d   Yi, Guanghui ^e   Zhang, Qiuju ^a   Yuan, Zhonghua ^e   Tang, Kechao ^e  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b Central South University   (China)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e Medicial School NanHua University   (China)

Author keywords

Adipocyte; CAS 133208 93 2; Diabetes; FFA; Glucose; Minipigs; NO 1886; TNF

Indexed keywords

4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; ENZYME ACTIVATOR; FATTY ACID; GLUCOSE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CELL SIZE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN RESPONSE; LIPID DIET; LIPID STORAGE; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL;

EID: 0346690101     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.09.008     Document Type: Article

References (21)

1. Granner D.K., O'Brien R.M. Molecular physiology and genetics of NIDDM. Importance of metabolic staging. Diabetes Care. 15:1992;369-396.
2. Elbein S.C., Hoffman M.D., Bragg K.L., Mayorga R.A. The genetics of NIDDM. An update. Diabetes Care. 17:1994;1523-1533.
3. Horton E.S. NIDDM the devastating disease. Diabetes Res. Clin. Pract. 28:1995;S3-S11.
4. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
5. Hotamisligil G.S., Budavari A., Murray D., Spiegelman B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor. J. Clin. Invest. 94:1994;1543-1549.
6. Hotamisligil G.S., Murray D.L., Choy L.N., Spiegelman B.M. Tumor necrosis factor inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. U.S.A. 91:1994;4854-4858.
7. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95:1995;2409-2415.
8. Saghizadeh M., Ong J.M., Garvey W.T., Henry R.R., Kern P.A. The expression of TNF- by human muscle. Relationship to insulin resistance. J. Clin. Invest. 97:1996;1111-1116.
9. Kern P.A. Potential role of TNF and lipoprotein lipase as candidate genes for obesity. J. Nutr. 127:1997;1917S-1922S.
10. Reaven G.M., Hollenbeck C., Jeng C.-Y., Wu M.S., Chen Y.-D. Measurement of plasma glucose free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 37:1988;1020-1024.
11. McGarry J.D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science (Washington, DC). 258:1992;766-770.
12. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. i:1963;785-789.
13. Randle P.J., Garland P.B., Newsholme E.A., Hales C.N. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann. N.Y. Acad. Sci. 131:1965;324-333.
14. Tsutsumi K., Inoue Y., Shima A., Iwasaki K., Kawamura M., Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high-density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest. 92:1993;411-417.
15. Tsutsumi K., Inoue Y., Shima A., Murase T. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes. 44:1995;414-417.
16. Hagi A., Hirai I., Kohri H., Tsutsumi K. The novel compound NO-1886 activates lipoprotein lipase in primary cultured adipose and skeletal muscle cells. Biol. Pharm. Bull. 20:1997;1108-1110.
17. Kusunoki M., Haral T., Tsutsumi K., Nakamura T., Miyata T., Sakakibara F.et al. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia. 43:2000;875-880.
18. Yin W., Tsutsumi K., Yuan Z., Yang B. Effects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild diabetic rabbits. Arzneimittelforschung. 52:2002;610-614.
19. Kahn B., Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 106:2000;473-481.
20. Doi M, Kondo Y, Tsutsumi K. LPL activator NO-1886 (ibrolipim) accelerates the mRNA expression of fatty acid oxidation related enzymes in rat liver. Matabolism, in press.
21. Ohara M., Tsutsumi K., Ohsawa N. Suppression of carcass weight loss in cachexia in rats bearing leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator. Metabolism. 47:1998;101-105.